Table 2 General analyses of the high-throughput ATAC-seq.
From: Characterization of cancer omics and drug perturbations in panels of lung cancer cells
| Â | Â | Total data points* (% passed QC) | Average numbers per data point | |||
|---|---|---|---|---|---|---|
Mapped reads | %mapped | %chrM in mapped | MACS peaks | |||
Dataset-1 (4 conc. × 3 time points) | A549 | 251 (87%) | 11,286,126 | 79% | 17% | 35,355 |
H1299 | 269 (93%) | 5,821,704 | 69% | 65% | 17,184 | |
H1648 | 264 (92%) | 5,943,835 | 71% | 58% | 18,571 | |
H2347 | 276 (96%) | 4,752,301 | 70% | 64% | 26,166 | |
II-18 | 256 (89%) | 5,838,263 | 70% | 64% | 18641 | |
Dataset-2 (1 conc. × 1 time point) | 23 cells | 2077 (94%) | 8,158,509 | 71% | 57% | 17,734 |
